Prescient Therapeutics LimitedASX: PTX

Appendix 4D and Half Year Financial Report

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 20 pages · English

Summary by 6ix AI

The report indicates a significant decline in revenues from ordinary activities and an increase in losses attributable to the owners of the company compared to the previous period. Operating expenses rose due to heightened clinical trial activities and share-based payment expenses during the half-year. The company reported no dividends paid or declared during this financial period.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Prescient Therapeutics Limited on 6ix

Earlier from Prescient Therapeutics

Later from Prescient Therapeutics

All Prescient Therapeutics news releases